Phase 3Status unknown
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
A Non-randomized, Multicenter, Confirmatory Study by Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury
- Sponsor
- Kringle Pharma, Inc. (Industry)
- Enrollment
- 25 planned
- Conditions
- Acute Spinal Cord Injury
- Interventions
- KP-100IT
- Ages
- adults, older adults
- Registry
- NCT04475224
Full record on ClinicalTrials.gov
From the registry
This study is non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.
Primary outcomes
- Percentage of subjects with an improvement of at least two AIS (American Spinal Injury Association) grade, A to C/D, at 24 weeks after administration
History
Study completion
Primary completion
Last registry update
Registered
Started